1932
0

Annual Review of Medicine

Volume 76, 2025

New Approaches to Respiratory Syncytial Virus Prevention and Treatment

  • Emmanuel B. Walter1 and Flor M. Munoz2
  • 1Department of Pediatrics and Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA; email: [email protected] 2Department of Pediatrics and Department of Molecular Virology and Microbiology, Baylor College of Medicine, and Texas Children's Hospital, Houston, Texas, USA
  • Vol. 76:13-28 (Volume publication date January 2025)
  • First published as a Review in Advance on December 10, 2024
  • Copyright © 2025 by the author(s).
    This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information.

Abstract

There have been several recent advances in the prevention of lower respiratory tract disease (LRTD) due to respiratory syncytial virus (RSV) infection in older adults and young children. Three different vaccines are now approved for use in older adults; one of these vaccines is also approved for use in pregnant individuals for the prevention of LRTD due to RSV in their infants. In addition, a new monoclonal antibody is available to prevent RSV LRTD in infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Despite these advances in prevention efforts, specific antiviral treatment options for RSV infection remain limited. Several promising compounds remain in development.

Keyword(s): antiviral, monoclonal antibody, respiratory syncytial virus, RSV, vaccine
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-061323-073934
2025-01-27
2025-06-22
Loading full text...

Full text loading...

/deliver/fulltext/med/76/1/annurev-med-061323-073934.html?itemId=/content/journals/10.1146/annurev-med-061323-073934&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Haynes AK, Prill MM, Iwane MK, . 2014.. Respiratory syncytial virus—United States, July 2012–June 2014. . Morb. Mortal. Wkly. Rep. 63::1133–36
     [Google Scholar]
  2. 2.
    Hall CB. 2001.. Respiratory syncytial virus and parainfluenza virus. . N. Engl. J. Med. 344::1917–28
     [Google Scholar]
  3. 3.
    Nair H, Nokes DJ, Gessner BD, et al. 2010.. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. . Lancet 375::1545–55
     [Google Scholar]
  4. 4.
    Hall CB, Weinberg GA, Iwane MK, et al. 2009.. The burden of respiratory syncytial virus infection in young children. . N. Engl. J. Med. 360::588–98
     [Google Scholar]
  5. 5.
    Hansen CL, Chaves SS, Demont C, Viboud C. 2022.. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. . JAMA Netw. Open 5::e220527
     [Google Scholar]
  6. 6.
    CDC. 2024.. RSV in infants and young children. Last updated Aug. 30. https://www.cdc.gov/rsv/infants-young-children/index.html
    [Google Scholar]
  7. 7.
    Widmer K, Zhu Y, Williams JV, et al. 2012.. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. . J. Infect. Dis. 206::56–62
     [Google Scholar]
  8. 8.
    Dowell SF, Anderson LJ, Gary HE Jr., et al. 1996.. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. . J. Infect. Dis. 174::456–62
     [Google Scholar]
  9. 9.
    Branche AR, Saiman L, Walsh EE, et al. 2022.. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020. . Clin. Infect. Dis. 74::1004–11
     [Google Scholar]
  10. 10.
    CDC. 2024.. RSV in adults. Last updated Aug. 30. https://www.cdc.gov/rsv/older-adults/?CDC
    [Google Scholar]
  11. 11.
    McLaughlin JM, Khan F, Begier E, et al. 2022.. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. . Open Forum Infect. Dis. 9::ofac300
     [Google Scholar]
  12. 12.
    Liu C, Ho DY, Boeckh M. 2019.. Respiratory viral infections in transplant recipients. . In Principles and Practice of Transplant Infectious Diseases, ed. A Safdar , pp. 679–95. New York:: Springer
     [Google Scholar]
  13. 13.
    Collins PL, Fearns R, Graham BS. 2013.. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. . Curr. Top. Microbiol. Immunol. 372::3–38
     [Google Scholar]
  14. 14.
    Wertz GW, Moudy RM. 2004.. Antigenic and genetic variation in human respiratory syncytial virus. . Pediatr. Infect. Dis. J. 23::S19–24
     [Google Scholar]
  15. 15.
    Hall CB, Walsh EE, Schnabel KC, et al. 1990.. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. . J. Infect. Dis. 162::1283–90
     [Google Scholar]
  16. 16.
    Kapikian AZ, Mitchell RH, Chanock RM, et al. 1969.. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. . Am. J. Epidemiol. 89::405–21
     [Google Scholar]
  17. 17.
    Fulginiti VA, Eller JJ, Sieber OF, et al. 1969.. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. . Am. J. Epidemiol. 89::435–48
     [Google Scholar]
  18. 18.
    Kim HW, Canchola JG, Brandt CD, et al. 1969.. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. . Am. J. Epidemiol. 89::422–34
     [Google Scholar]
  19. 19.
    Murphy BR, Prince GA, Walsh EE, et al. 1986.. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. . J. Clin. Microbiol. 24::197–202
     [Google Scholar]
  20. 20.
    Graham BS, Henderson GS, Tang YW, et al. 1993.. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. . J. Immunol. 151::2032–40
     [Google Scholar]
  21. 21.
    McLellan JS. 2015.. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. . Curr. Opin. Virol. 11::70–75
     [Google Scholar]
  22. 22.
    Walsh EE, Perez Marc G, Zareba AM, et al. 2023.. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. . N. Engl. J. Med. 388::1465–77
     [Google Scholar]
  23. 23.
    Papi A, Ison MG, Langley JM, et al. 2023.. Respiratory syncytial virus prefusion F protein vaccine in older adults. . N. Engl. J. Med. 388::595–608
     [Google Scholar]
  24. 24.
    Wilson E, Goswami J, Baqui AH, et al. 2023.. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. . N. Engl. J. Med. 389::2233–44
     [Google Scholar]
  25. 25.
    Schmoele-Thoma B, Zareba AM, Jiang Q, et al. 2022.. Vaccine efficacy in adults in a respiratory syncytial virus challenge study. . N. Engl. J. Med. 386::2377–86
     [Google Scholar]
  26. 26.
    CDC. 2024.. Post-licensure safety monitoring of respiratory syncytial virus (RSV) vaccines in adults aged ≥60 years. Present., CDC. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/05-RSV-Adults-Shimabukuro-508.pdf
    [Google Scholar]
  27. 27.
    Melgar M, Britton A, Roper LE, et al. 2023.. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. . Morb. Mortal. Wkly. Rep. 72::793–801
     [Google Scholar]
  28. 28.
    Advis. Comm. Immun. Pract. (ACIP). 2024.. ACIP presentation slides: June 26–28, 2024 meeting. https://www.cdc.gov/vaccines/acip/meetings/slides-2024-06-26-28.html
    [Google Scholar]
  29. 29.
    Schwarz TF, Hwang SJ, Ylisastigui P, et al. 2023.. Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial. . J. Infect. Dis. 230::e102–10
     [Google Scholar]
  30. 30.
    Ison MG, Papi A, Athan E, et al. 2024.. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. . Clin. Infect. Dis. 78::1732–44
     [Google Scholar]
  31. 31.
    Hogye SI, Jansen PW, Lucassen N, Keizer R. 2022.. The relation between harsh parenting and bullying involvement and the moderating role of child inhibitory control: a population-based study. . Aggress. Behav. 48::141–51
     [Google Scholar]
  32. 32.
    Chandler R, Montenegro N, Llorach C, et al. 2024.. Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted RSV prefusion F protein–based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial. . Clin. Infect. Dis. In press. https://doi.org/10.1093/cid/ciad786
    [Google Scholar]
  33. 33.
    Athan E, Baber J, Quan K, et al. 2024.. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. . Clin. Infect. Dis. 78::1360–68
     [Google Scholar]
  34. 34.
    Chanock R, Finberg L. 1957.. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. . Am. J. Hyg. 66::291–300
     [Google Scholar]
  35. 35.
    Glezen WP, Taber LH, Frank AL, Kasel JA. 1986.. Risk of primary infection and reinfection with respiratory syncytial virus. . Am. J. Dis. Child. 140::543–46
     [Google Scholar]
  36. 36.
    Kasel JA, Walsh EE, Frank AL, et al. 1987.. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. . Viral Immunol. 1::199–205
     [Google Scholar]
  37. 37.
    Kasel JA, Frank AL, Keitel WA, Taber LH, Glezen WP. 1984.. Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. . J. Virol. 52::828–32
     [Google Scholar]
  38. 38.
    Piedra PA, Grace S, Jewell A, et al. 1996.. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. . Pediatr. Infect. Dis. J. 15::23–31
     [Google Scholar]
  39. 39.
    Piedra PA, Cron SG, Jewell A, et al. 2003.. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. . Vaccine 21::2448–60
     [Google Scholar]
  40. 40.
    Piedra PA. 2003.. Clinical experience with respiratory syncytial virus vaccines. . Pediatr. Infect. Dis. J. 22::S94–99
     [Google Scholar]
  41. 41.
    Groothuis JR, King SJ, Hogerman DA, et al. 1998.. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. . J. Infect. Dis. 177::467–69
     [Google Scholar]
  42. 42.
    Munoz FM, Piedra PA, Glezen WP. 2003.. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. . Vaccine 21::3465–67
     [Google Scholar]
  43. 43.
    Karron RA, Atwell JE, McFarland EJ, et al. 2021.. Live-attenuated vaccines prevent respiratory syncytial virus–associated illness in young children. . Am. J. Respir. Crit. Care Med. 203::594–603
     [Google Scholar]
  44. 44.
    Karron RA, Buchholz UJ, Collins PL. 2013.. Live-attenuated respiratory syncytial virus vaccines. . Curr. Top. Microbiol. Immunol. 372::259–84
     [Google Scholar]
  45. 45.
    Schickli JH, Dubovsky F, Tang RS. 2009.. Challenges in developing a pediatric RSV vaccine. . Hum. Vaccines 5::582–91
     [Google Scholar]
  46. 46.
    Anderson LJ, Dormitzer PR, Nokes DJ, et al. 2013.. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. . Vaccine 31:(Suppl. 2):B209–15
     [Google Scholar]
  47. 47.
    Mazur NI, Higgins D, Nunes MC, et al. 2018.. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. . Lancet Infect. Dis. 18::e295–311
     [Google Scholar]
  48. 48.
    Gerretsen HE, Sande CJ. 2017.. Development of respiratory syncytial virus (RSV) vaccines for infants. . J. Infect. 74:(Suppl. 1):S143–46
     [Google Scholar]
  49. 49.
    Higgins D, Trujillo C, Keech C. 2016.. Advances in RSV vaccine research and development: a global agenda. . Vaccine 34::2870–75
     [Google Scholar]
  50. 50.
    McFarland EJ, Karron RA, Muresan P, et al. 2020.. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children. . J. Infect. Dis. 221::2050–59
     [Google Scholar]
  51. 51.
    Cunningham CK, Karron RA, Muresan P, et al. 2022.. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV-seronegative children. . J. Infect. Dis. 226::2069–78
     [Google Scholar]
  52. 52.
    Pfizer. 2023.. US FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults. Press Release, Pfizer:. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention
    [Google Scholar]
  53. 53.
    Moderna. 2024.. A clinical trial of a respiratory syncytial virus (RSV) vaccine for adults and children. Study:, Moderna. Accessed Sep. 4, 2024. https://trials.modernatx.com/study/?id=mRNA-1345-P101
    [Google Scholar]
  54. 54.
    Moderna. A clinical trial of an RSV vaccine for children ages 2–17. Study:, Moderna. Accessed Sep. 4, 2024. https://trials.modernatx.com/study/?id=mRNA-1345-P202
    [Google Scholar]
  55. 55.
    Mejias A, Ramilo O. 2024.. RSV prevention within reach for older infants and toddlers: the role of active immunization. . J. Pediatr. Infect. Dis. Soc. 13::S125–30
     [Google Scholar]
  56. 56.
    Mazur NI, Terstappen J, Baral R, et al. 2023.. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. . Lancet Infect. Dis. 23::e2–21
     [Google Scholar]
  57. 57.
    Karron RA, Luongo C, Woods S, et al. 2024.. Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children. . J. Infect. Dis. 229::346–54
     [Google Scholar]
  58. 58.
    Shan J, Britton PN, King CL, Booy R. 2021.. The immunogenicity and safety of respiratory syncytial virus vaccines in development: a systematic review. . Influenza Other Respir. Viruses 15::539–51
     [Google Scholar]
  59. 59.
    Ginsburg AS, Srikantiah P. 2021.. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. . Lancet Glob. Health 9::e1644–45
     [Google Scholar]
  60. 60.
    Topalidou X, Kalergis AM, Papazisis G. 2023.. Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines. . Pathogens 12::1259
     [Google Scholar]
  61. 61.
    Karron RA, Luongo C, Mateo JS, et al. 2020.. Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/DeltaNS2/Delta1313/I1314L in RSV-seronegative children. . J. Infect. Dis. 222::82–91
     [Google Scholar]
  62. 62.
    Meissa Vaccines. 2023.. Meissa's positive clinical data for the first RSV vaccine designed to protect infants & toddlers. Press Release, Meissa Vaccines. https://www.meissavaccines.com/post/meissa-s-positive-clinical-data-for-the-first-rsv-vaccine-designed-to-protect-infants-toddlers
    [Google Scholar]
  63. 63.
    Blue Lake Biotechnology. 2024.. A study of BLB-201 RSV vaccine in infants and children. Study Rec.:, Blue Lake Biotechnology. https://clinicaltrials.gov/study/NCT05655182?cond=NCT05655182&rank=1
    [Google Scholar]
  64. 64.
    Meissa Vaccines. 2022.. Safety and immunogenicity of an intranasal vaccine for respiratory syncytial virus in seronegative children 6–36 months. Study Rec., Meissa Vaccines. https://clinicaltrials.gov/study/NCT04909021?cond=NCT04909021&rank=1
    [Google Scholar]
  65. 65.
    Kampmann B, Madhi SA, Munjal I, et al. 2023.. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. . N. Engl. J. Med. 388::1451–64
     [Google Scholar]
  66. 66.
    Simoes EAF, Center KJ, Tita ATN, et al. 2022.. Prefusion F protein–based respiratory syncytial virus immunization in pregnancy. . N. Engl. J. Med. 386::1615–26
     [Google Scholar]
  67. 67.
    Fleming-Dutra KE, Jones JM, Roper LE, et al. 2023.. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. . Morb. Mortal. Wkly. Rep. 72::1115–22
     [Google Scholar]
  68. 68.
    Committee on Infectious Diseases, Bronchiolitis Guidelines Committee, American Academy of Pediatrics. 2014.. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. . Pediatrics 134::e620–38
     [Google Scholar]
  69. 69.
    Tang A, Chen Z, Cox KS, et al. 2019.. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. . Nat. Commun. 10::4153
     [Google Scholar]
  70. 70.
    Aliprantis AO, Wolford D, Caro L, et al. 2021.. A phase 1 randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults. . Clin. Pharmacol. Drug Dev. 10::556–66
     [Google Scholar]
  71. 71.
    Griffin MP, Yuan Y, Takas T, et al. 2020.. Single-dose nirsevimab for prevention of RSV in preterm infants. . N. Engl. J. Med. 383::415–25
     [Google Scholar]
  72. 72.
    Hammitt LL, Dagan R, Yuan Y, et al. 2022.. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. . N. Engl. J. Med. 386::837–46
     [Google Scholar]
  73. 73.
    Muller WJ, Madhi SA, Seoane Nunez B, et al. 2023.. Nirsevimab for prevention of RSV in term and late-preterm infants. . N. Engl. J. Med. 388::1533–34
     [Google Scholar]
  74. 74.
    Domachowske J, Madhi SA, Simoes EAF, et al. 2022.. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. . N. Engl. J. Med. 386::892–94
     [Google Scholar]
  75. 75.
    Jones JM, Fleming-Dutra KE, Prill MM, et al. 2023.. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. . Morb. Mortal. Wkly. Rep. 72::920–25
     [Google Scholar]
  76. 76.
    Moline HL, Tannis A, Toepfer AP, et al. 2024.. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus–associated hospitalization among infants entering their first respiratory syncytial virus season—New Vaccine Surveillance Network, October 2023–February 2024. . Morb. Mortal. Wkly. Rep. 73::209–14
     [Google Scholar]
  77. 77.
    Ares-Gomez S, Mallah N, Santiago-Perez MI, et al. 2024.. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. . Lancet Infect. Dis. 24::817–28
     [Google Scholar]
  78. 78.
    Martinon-Torres F, Miras-Carballal S, Duran-Parrondo C. 2023.. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. . Eurosurveillance 28::2300606
     [Google Scholar]
  79. 79.
    Feikin DR, Karron RA, Saha SK, et al. 2024.. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. . Lancet Infect. Dis. 24::e318–27
     [Google Scholar]
  80. 80.
    Bausch Health. 2019.. VIRAZOLE® (ribavirin for inhalation solution, USP): prescribing information. Prescr. Inf., Bausch Health. https://pi.bauschhealth.com/globalassets/BHC/PI/Virazole-PI.pdf
    [Google Scholar]
  81. 81.
    Taber LH, Knight V, Gilbert BE, et al. 1983.. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. . Pediatrics 72::613–18
     [Google Scholar]
  82. 82.
    Hall CB, McBride JT, Walsh EE, et al. 1983.. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. . N. Engl. J. Med. 308::1443–47
     [Google Scholar]
  83. 83.
    Randolph AG, Wang EE. 1996.. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. . Arch. Pediatr. Adolesc Med. 150::942–47
     [Google Scholar]
  84. 84.
    CDC. 1988.. Assessing exposures of health-care personnel to aerosols of ribavirin—California. . Morb. Mortal. Wkly. Rep. 37::560–63
     [Google Scholar]
  85. 85.
    American Academy of Pediatrics Committee on Infectious Diseases. 1996.. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. . Pediatrics 97::137–40
     [Google Scholar]
  86. 86.
    Chemaly RF, Shah DP, Boeckh MJ. 2014.. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. . Clin. Infect. Dis. 59:(Suppl. 5):S344–51
     [Google Scholar]
  87. 87.
    Manuel O, Estabrook M, American Society of Transplantation Infectious Diseases Community of Practice. 2019.. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. . Clin. Transplant. 33::e13511
     [Google Scholar]
  88. 88.
    Nicholson EG, Munoz FM. 2018.. A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children. . Clin. Ther. 40::1268–81
     [Google Scholar]
  89. 89.
    DeVincenzo JP, Whitley RJ, Mackman RL, et al. 2014.. Oral GS-5806 activity in a respiratory syncytial virus challenge study. . N. Engl. J. Med. 371::711–22
     [Google Scholar]
  90. 90.
    DeVincenzo J, Tait D, Efthimiou J, et al. 2020.. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. . Antimicrob. Agents Chemother. 64::e01884-19
     [Google Scholar]
  91. 91.
    Stevens M, Rusch S, DeVincenzo J, et al. 2018.. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. . J. Infect. Dis. 218::748–56
     [Google Scholar]
  92. 92.
    Chemaly RF, Dadwal SS, Bergeron A, et al. 2020.. A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. . Clin. Infect. Dis. 71::2777–86
     [Google Scholar]
  93. 93.
    Marty FM, Chemaly RF, Mullane KM, et al. 2020.. A phase 2B, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. . Clin. Infect. Dis. 71::2787–95
     [Google Scholar]
  94. 94.
    Gottlieb J, Torres F, Haddad T, et al. 2023.. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant. . J. Heart Lung Transplant. 42::908–16
     [Google Scholar]
  95. 95.
    Huang LM, Schibler A, Huang YC, et al. 2023.. Safety and efficacy of AK0529 in respiratory syncytial virus–infected infant patients: a phase 2 proof-of-concept trial. . Influenza Other Respir. Viruses 17::e13176
     [Google Scholar]
  96. 96.
    Ahmad A, Eze K, Noulin N, et al. 2022.. EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge. . N. Engl. J. Med. 386::655–66
     [Google Scholar]
  97. 97.
    Oey A, McClure M, Symons JA, et al. 2023.. Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: safety, efficacy, and pharmacokinetic results. . PLOS ONE 18::e0288271
     [Google Scholar]
  98. 98.
    DeVincenzo J, Cass L, Murray A, et al. 2022.. Safety and antiviral effects of nebulized PC786 in a respiratory syncytial virus challenge study. . J. Infect. Dis. 225::2087–96
     [Google Scholar]
  99. 99.
    DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. 2010.. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. . PNAS 107::8800–5
     [Google Scholar]
  100. 100.
    Gottlieb J, Zamora MR, Hodges T, et al. 2016.. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. . J. Heart Lung Transplant. 35::213–21
     [Google Scholar]
  101. 101.
    McFarland EJ, Karron RA, Muresan P, et al. 2020.. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. . J. Infect. Dis. 221::534–43
     [Google Scholar]
/content/journals/10.1146/annurev-med-061323-073934
Loading
New Approaches to Respiratory Syncytial Virus Prevention and Treatment
Annual Review of Medicine 76, 13 (2025); https://doi.org/10.1146/annurev-med-061323-073934
/content/journals/10.1146/annurev-med-061323-073934
/content/journals/10.1146/annurev-med-061323-073934
Loading

Data & Media loading...

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error